Novo Nordisk returns to the M&A market, seeking to revitalize its obesity business segment
Novo Nordisk CEO Mike Doustdar stated that the company is open to the size of transactions as long as they complement the company's existing assets and provide value.
"We are looking at both big deals and small transactions," said Mike Doustdar during the JP Morgan Healthcare Conference held in San Francisco, USA. "As long as it can complement our existing assets, we can spend heavily on acquisitions. But it must provide value and be significantly better than our current products."
By the end of 2025, after losing a bidding war for the American biotechnology company Metsera Inc. to Pfizer, Novo Nordisk is actively seeking transaction opportunities to strengthen its obesity product portfolio. (Bloomberg)
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments